Antibody response to merkel cell polyomavirus associated with incident lymphoma in the epilymph case-control study in Spain

Claudia Robles, Andre Poloczek, Delphine Casabonne, Eva Gonzalez-Barca, Ramon Bosch, Yolanda Benavente, Raphael P Viscidi, Silvia De Sanjosé

Research output: Contribution to journalArticle

Abstract

Background: Merkel cell polyomavirus (MCV) has been identified as the cause of Merkel cell carcinoma. The increased incidence of chronic lymphocytic leukemia in Merkel cell cancer cohorts and the lymphotropic properties of the virus suggest a possible viral association with lymphomagenesis. To investigate this potential role, we explored seroreactivity against MCV VP1 capsids within the Epilymph case-control study in Spain. Methods: Serum samples from 468 incident lymphomas, categorized into up to 11 entities, and 522 controls frequency matched by age, sex, and recruitment center were tested for MCV antibodies by enzyme immunoassay using Virus-Like-Particles. Adjusted multinomial logistic regression was used to estimate the OR and 95% confidence interval (CI) associated to MCV seroprevalence. Immunosuppressed subjects were excluded. Results: MCV seroprevalence was 82% in controls and 85% in lymphoma cases. Among 11 lymphoma categories, MCV seropositivity was significantly higher in diffuse large B-cell lymphomas (DLBCL; 96.4%; OR = 6.1, 95%CI = 1.9-19.8), as compared with controls. MCV prevalences were also higher in follicular lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma, and mature T-cell lymphoma but differences did not reach statistical significance. Lower prevalences were observed for multiple myeloma and other B-cell lymphoma. Exclusion of samples collected after start of treatment did not change the results. In a subset analysis, no significant association was observed between BKV and JCV seroprevalence and DLBCL. Conclusion: The association observed between serologic evidence of MCV exposure and DLBCL warrants further research. Impact: MCV might be involved in the pathway of DLBCL and other lymphomas.

Original languageEnglish (US)
Pages (from-to)1592-1598
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume21
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Merkel cell polyomavirus
Spain
Antibody Formation
Case-Control Studies
Lymphoma
Seroepidemiologic Studies
Merkel Cell Carcinoma
B-Cell Chronic Lymphocytic Leukemia
Confidence Intervals
Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
T-Cell Lymphoma
Capsid
B-Cell Lymphoma
Multiple Myeloma
Hodgkin Disease
Immunoenzyme Techniques
Virion
Logistic Models

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Antibody response to merkel cell polyomavirus associated with incident lymphoma in the epilymph case-control study in Spain. / Robles, Claudia; Poloczek, Andre; Casabonne, Delphine; Gonzalez-Barca, Eva; Bosch, Ramon; Benavente, Yolanda; Viscidi, Raphael P; De Sanjosé, Silvia.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 21, No. 9, 09.2012, p. 1592-1598.

Research output: Contribution to journalArticle

Robles, Claudia ; Poloczek, Andre ; Casabonne, Delphine ; Gonzalez-Barca, Eva ; Bosch, Ramon ; Benavente, Yolanda ; Viscidi, Raphael P ; De Sanjosé, Silvia. / Antibody response to merkel cell polyomavirus associated with incident lymphoma in the epilymph case-control study in Spain. In: Cancer Epidemiology Biomarkers and Prevention. 2012 ; Vol. 21, No. 9. pp. 1592-1598.
@article{8cc5fab6ff7c412399788a4241ce09a9,
title = "Antibody response to merkel cell polyomavirus associated with incident lymphoma in the epilymph case-control study in Spain",
abstract = "Background: Merkel cell polyomavirus (MCV) has been identified as the cause of Merkel cell carcinoma. The increased incidence of chronic lymphocytic leukemia in Merkel cell cancer cohorts and the lymphotropic properties of the virus suggest a possible viral association with lymphomagenesis. To investigate this potential role, we explored seroreactivity against MCV VP1 capsids within the Epilymph case-control study in Spain. Methods: Serum samples from 468 incident lymphomas, categorized into up to 11 entities, and 522 controls frequency matched by age, sex, and recruitment center were tested for MCV antibodies by enzyme immunoassay using Virus-Like-Particles. Adjusted multinomial logistic regression was used to estimate the OR and 95{\%} confidence interval (CI) associated to MCV seroprevalence. Immunosuppressed subjects were excluded. Results: MCV seroprevalence was 82{\%} in controls and 85{\%} in lymphoma cases. Among 11 lymphoma categories, MCV seropositivity was significantly higher in diffuse large B-cell lymphomas (DLBCL; 96.4{\%}; OR = 6.1, 95{\%}CI = 1.9-19.8), as compared with controls. MCV prevalences were also higher in follicular lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma, and mature T-cell lymphoma but differences did not reach statistical significance. Lower prevalences were observed for multiple myeloma and other B-cell lymphoma. Exclusion of samples collected after start of treatment did not change the results. In a subset analysis, no significant association was observed between BKV and JCV seroprevalence and DLBCL. Conclusion: The association observed between serologic evidence of MCV exposure and DLBCL warrants further research. Impact: MCV might be involved in the pathway of DLBCL and other lymphomas.",
author = "Claudia Robles and Andre Poloczek and Delphine Casabonne and Eva Gonzalez-Barca and Ramon Bosch and Yolanda Benavente and Viscidi, {Raphael P} and {De Sanjos{\'e}}, Silvia",
year = "2012",
month = "9",
doi = "10.1158/1055-9965.EPI-11-1140",
language = "English (US)",
volume = "21",
pages = "1592--1598",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Antibody response to merkel cell polyomavirus associated with incident lymphoma in the epilymph case-control study in Spain

AU - Robles, Claudia

AU - Poloczek, Andre

AU - Casabonne, Delphine

AU - Gonzalez-Barca, Eva

AU - Bosch, Ramon

AU - Benavente, Yolanda

AU - Viscidi, Raphael P

AU - De Sanjosé, Silvia

PY - 2012/9

Y1 - 2012/9

N2 - Background: Merkel cell polyomavirus (MCV) has been identified as the cause of Merkel cell carcinoma. The increased incidence of chronic lymphocytic leukemia in Merkel cell cancer cohorts and the lymphotropic properties of the virus suggest a possible viral association with lymphomagenesis. To investigate this potential role, we explored seroreactivity against MCV VP1 capsids within the Epilymph case-control study in Spain. Methods: Serum samples from 468 incident lymphomas, categorized into up to 11 entities, and 522 controls frequency matched by age, sex, and recruitment center were tested for MCV antibodies by enzyme immunoassay using Virus-Like-Particles. Adjusted multinomial logistic regression was used to estimate the OR and 95% confidence interval (CI) associated to MCV seroprevalence. Immunosuppressed subjects were excluded. Results: MCV seroprevalence was 82% in controls and 85% in lymphoma cases. Among 11 lymphoma categories, MCV seropositivity was significantly higher in diffuse large B-cell lymphomas (DLBCL; 96.4%; OR = 6.1, 95%CI = 1.9-19.8), as compared with controls. MCV prevalences were also higher in follicular lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma, and mature T-cell lymphoma but differences did not reach statistical significance. Lower prevalences were observed for multiple myeloma and other B-cell lymphoma. Exclusion of samples collected after start of treatment did not change the results. In a subset analysis, no significant association was observed between BKV and JCV seroprevalence and DLBCL. Conclusion: The association observed between serologic evidence of MCV exposure and DLBCL warrants further research. Impact: MCV might be involved in the pathway of DLBCL and other lymphomas.

AB - Background: Merkel cell polyomavirus (MCV) has been identified as the cause of Merkel cell carcinoma. The increased incidence of chronic lymphocytic leukemia in Merkel cell cancer cohorts and the lymphotropic properties of the virus suggest a possible viral association with lymphomagenesis. To investigate this potential role, we explored seroreactivity against MCV VP1 capsids within the Epilymph case-control study in Spain. Methods: Serum samples from 468 incident lymphomas, categorized into up to 11 entities, and 522 controls frequency matched by age, sex, and recruitment center were tested for MCV antibodies by enzyme immunoassay using Virus-Like-Particles. Adjusted multinomial logistic regression was used to estimate the OR and 95% confidence interval (CI) associated to MCV seroprevalence. Immunosuppressed subjects were excluded. Results: MCV seroprevalence was 82% in controls and 85% in lymphoma cases. Among 11 lymphoma categories, MCV seropositivity was significantly higher in diffuse large B-cell lymphomas (DLBCL; 96.4%; OR = 6.1, 95%CI = 1.9-19.8), as compared with controls. MCV prevalences were also higher in follicular lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma, and mature T-cell lymphoma but differences did not reach statistical significance. Lower prevalences were observed for multiple myeloma and other B-cell lymphoma. Exclusion of samples collected after start of treatment did not change the results. In a subset analysis, no significant association was observed between BKV and JCV seroprevalence and DLBCL. Conclusion: The association observed between serologic evidence of MCV exposure and DLBCL warrants further research. Impact: MCV might be involved in the pathway of DLBCL and other lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=84866163336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866163336&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-11-1140

DO - 10.1158/1055-9965.EPI-11-1140

M3 - Article

C2 - 22781028

AN - SCOPUS:84866163336

VL - 21

SP - 1592

EP - 1598

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 9

ER -